




**Figure 1: Chemical Structures of Illustrative Nucleosides**




$\beta$ -D-2'-CH<sub>3</sub>-riboG




$\beta$ -D-2'-CH<sub>3</sub>-riboC




$\beta$ -D-2'-CH<sub>3</sub>-riboU




$\beta$ -D-2'-CH<sub>3</sub>-riboA




$\beta$ -D-2'-CH<sub>3</sub>-riboI




$\beta$ -D-2'-CH<sub>3</sub>-riboT




$\beta$ -D-1'-CH<sub>3</sub>-riboA



$\beta$ -D-1'-CH<sub>3</sub>-riboG




FIAU




Ribavirin


Figure 2: Screening Pharmacokinetics of  $\beta$ -D-2'-CH<sub>3</sub>-riboG in Cynomolgus Monkeys



**Figure 3: Pharmacokinetics of  $\beta$ -D-2'-CH<sub>3</sub>-riboG in Cynomolgus Monkeys**






**Figure 3a**





**Figure 3b**

Figure 4: BVDV Cell Protection Assay (CPA) Of  $\beta$ -D-2'-CH<sub>3</sub>-riboG



**Figure 5: BVDV Cell Protection Assay (CPA) of Ribavirin**



### Cell Protection Assay




Figure 6: BVDV Cell Protection Assays




Figure 7: Plaque Purified BVDV




Figure 8: BVDV Plaque Assay of β-D-2'-CH<sub>3</sub>-riboU





Figure 9: Yield Reduction Assay of  $\beta$ -D-2'-CH<sub>3</sub>-riboG



4-log virus reduction at 9  $\mu\text{M}$

Figure 10: BVDV Yield Reduction Assay for  $\beta$ -D-2'-CH<sub>3</sub>-riboC

